2 Stocks That Could Double Your Money in 2023
Earning outsize returns in the stock market over a short period can be exciting, but doing so over the long run is even better. Can some companies provide both? Yes, especially those relatively small corporations that have yet to become household names. After all, many currently well-established companies were once small- or mid-cap stocks.
That's why it's worth keeping an eye on promising corporations on the smaller side. With that as a backdrop, let's look at two stocks along those lines: Axsome Therapeutics (NASDAQ: AXSM) and Bluebird Bio (NASDAQ: BLUE). These biotechs could deliver excellent returns this year, but it's essential to look carefully at their risk-reward profiles before pulling the trigger.
Axsome Therapeutics is a mid-cap drugmaker coming off a solid performance in 2022, during which its shares more than doubled. The company could carry this momentum into this year. Axsome is launching Auvelity, a fast-acting treatment for depression that earned approval in August. And there are other catalysts on the way for the biotech.
Source Fool.com
